|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BRD8 |
Gene summary for BRD8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BRD8 | Gene ID | 10902 |
| Gene name | bromodomain containing 8 | |
| Gene Alias | SMAP | |
| Cytomap | 5q31.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H0E9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10902 | BRD8 | LZE2T | Human | Esophagus | ESCC | 1.14e-05 | 5.33e-01 | 0.082 |
| 10902 | BRD8 | LZE4T | Human | Esophagus | ESCC | 2.93e-11 | 2.79e-01 | 0.0811 |
| 10902 | BRD8 | LZE7T | Human | Esophagus | ESCC | 1.63e-04 | 1.57e-01 | 0.0667 |
| 10902 | BRD8 | LZE8T | Human | Esophagus | ESCC | 5.14e-05 | 1.26e-01 | 0.067 |
| 10902 | BRD8 | LZE20T | Human | Esophagus | ESCC | 3.11e-02 | 1.12e-01 | 0.0662 |
| 10902 | BRD8 | LZE22T | Human | Esophagus | ESCC | 3.07e-04 | 2.34e-01 | 0.068 |
| 10902 | BRD8 | LZE24T | Human | Esophagus | ESCC | 2.52e-15 | 2.62e-01 | 0.0596 |
| 10902 | BRD8 | LZE21T | Human | Esophagus | ESCC | 2.05e-02 | 1.08e-01 | 0.0655 |
| 10902 | BRD8 | LZE6T | Human | Esophagus | ESCC | 5.25e-04 | 9.76e-02 | 0.0845 |
| 10902 | BRD8 | P1T-E | Human | Esophagus | ESCC | 1.06e-08 | 4.66e-01 | 0.0875 |
| 10902 | BRD8 | P2T-E | Human | Esophagus | ESCC | 1.27e-34 | 6.29e-01 | 0.1177 |
| 10902 | BRD8 | P4T-E | Human | Esophagus | ESCC | 7.89e-14 | 2.95e-01 | 0.1323 |
| 10902 | BRD8 | P5T-E | Human | Esophagus | ESCC | 2.38e-14 | 2.60e-01 | 0.1327 |
| 10902 | BRD8 | P8T-E | Human | Esophagus | ESCC | 2.44e-21 | 3.81e-01 | 0.0889 |
| 10902 | BRD8 | P9T-E | Human | Esophagus | ESCC | 3.92e-11 | 1.85e-01 | 0.1131 |
| 10902 | BRD8 | P10T-E | Human | Esophagus | ESCC | 6.63e-15 | 2.42e-01 | 0.116 |
| 10902 | BRD8 | P11T-E | Human | Esophagus | ESCC | 4.47e-11 | 5.11e-01 | 0.1426 |
| 10902 | BRD8 | P12T-E | Human | Esophagus | ESCC | 1.48e-45 | 7.59e-01 | 0.1122 |
| 10902 | BRD8 | P15T-E | Human | Esophagus | ESCC | 2.93e-19 | 3.74e-01 | 0.1149 |
| 10902 | BRD8 | P16T-E | Human | Esophagus | ESCC | 2.06e-23 | 3.78e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
| GO:00439682 | Esophagus | ESCC | histone H2A acetylation | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
| GO:00064731 | Liver | Cirrhotic | protein acetylation | 84/4634 | 201/18723 | 7.50e-08 | 2.25e-06 | 84 |
| GO:00183941 | Liver | Cirrhotic | peptidyl-lysine acetylation | 73/4634 | 169/18723 | 1.08e-07 | 3.07e-06 | 73 |
| GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
| GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
| GO:00064751 | Liver | Cirrhotic | internal protein amino acid acetylation | 65/4634 | 160/18723 | 6.66e-06 | 1.04e-04 | 65 |
| GO:00183931 | Liver | Cirrhotic | internal peptidyl-lysine acetylation | 64/4634 | 158/18723 | 8.75e-06 | 1.29e-04 | 64 |
| GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
| GO:00165731 | Liver | Cirrhotic | histone acetylation | 61/4634 | 152/18723 | 1.97e-05 | 2.62e-04 | 61 |
| GO:0043967 | Liver | Cirrhotic | histone H4 acetylation | 31/4634 | 67/18723 | 1.03e-04 | 1.06e-03 | 31 |
| GO:0097066 | Liver | Cirrhotic | response to thyroid hormone | 15/4634 | 26/18723 | 3.43e-04 | 2.93e-03 | 15 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BRD8 | SNV | Missense_Mutation | novel | c.177C>A | p.Phe59Leu | p.F59L | Q9H0E9 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-A2-A1FX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| BRD8 | SNV | Missense_Mutation | c.779N>A | p.Ala260Asp | p.A260D | Q9H0E9 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| BRD8 | SNV | Missense_Mutation | c.457G>A | p.Glu153Lys | p.E153K | Q9H0E9 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| BRD8 | SNV | Missense_Mutation | rs764808196 | c.2713N>A | p.Glu905Lys | p.E905K | Q9H0E9 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| BRD8 | SNV | Missense_Mutation | novel | c.2053N>A | p.Asp685Asn | p.D685N | Q9H0E9 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRD8 | SNV | Missense_Mutation | novel | c.3302N>G | p.Pro1101Arg | p.P1101R | Q9H0E9 | protein_coding | deleterious(0.03) | benign(0.062) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| BRD8 | SNV | Missense_Mutation | novel | c.3145G>T | p.Gly1049Trp | p.G1049W | Q9H0E9 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
| BRD8 | SNV | Missense_Mutation | novel | c.2977N>A | p.Leu993Ile | p.L993I | Q9H0E9 | protein_coding | tolerated_low_confidence(0.42) | benign(0.003) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| BRD8 | insertion | Nonsense_Mutation | novel | c.2360_2361insAGGCCCAGTCACATGGGAGAAATCATGAGTAGGGGAATTAT | p.Asn787LysfsTer10 | p.N787Kfs*10 | Q9H0E9 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BRD8 | insertion | In_Frame_Ins | novel | c.2771_2772insTTATTCTAGACA | p.Leu924_Leu925insTyrSerArgGln | p.L924_L925insYSRQ | Q9H0E9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |